Delisting notice from the exchange
Open the filing on sec.gov
Biofrontera Inc. (BFRI)
Nasdaq: BFRI · Pharmaceutical Preparations · Woburn, MA · filing with the SEC since 2021
The companyfiscal 2025, as filed
Revenue$41.7M+11.7%
Net income-$10.5M+40.7%
Earnings per share$-1.04+67.7%
Operating cash flow-$13.4M-30.1%
Cash$6.4M+8.2%
Debtn/a
Shareholders’ equity$10.5M+136.4%
Shares, diluted10.2M+84.4%
Return on equity-100.5%
The recordfrom its filings
Filings in 202629
Newest filingOct 30 · 25-NSE
Annual reportMar 19, 2026
Quarterly reportAug 13, 2026
Next report due10-Q by Nov 14
Insider sales, 12 months$0.00
Insider buys, 12 months$0.00
Patents grantedn/a
Filer category<br>Emerging growth company
Trailing twelve months to Jun 2026Revenue $46.2MNet income -$6.4MCash from operations -$7.9Mthe four newest filed quarters added
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
As filed, in USD. Nothing here is a forecast.
News
Current report
Open the filing on sec.gov
Quarterly report
Open the filing on sec.gov
Results released
Open the filing on sec.gov
Large holder update, amended
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Employee stock plan registration
Open the filing on sec.gov
Annual report, amended
Open the filing on sec.gov
Current report
Open the filing on sec.gov
Nothing of this kind is on the record for this company yet.
An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.